Home > Oncology > ELCC 2022 > Lung Cancer Epidemiology > Lung cancer diagnosis with liquid biopsy of peripheral blood cells

Lung cancer diagnosis with liquid biopsy of peripheral blood cells

Presented By
Dr Andreas Thomsen, University of Freiburg, Germany
Presented by
Andreas Thomsen University of Freiburg, Germany
Conference
ELCC 2022
Doi
https://doi.org/10.55788/907caa66
A change in DNA damage sensitivity is a common feature amongst cancer patients. Liquid biopsy of blood samples can be used to distinguish early- and advanced-stage lung cancer patients from healthy donors. Liquid biopsy using peripheral blood sampling is a minimally invasive approach that permits investigating cancers in a cost-effective and patient-friendly manner. Several liquid biopsy assays, mostly targeting circulating tumour cells or ctDNA, have been introduced into clinical practice but their applicability for early-stage disease is limited due to low levels of circulating markers in the blood. On the other hand, peripheral blood mononuclear cells (PBMCs) are present in large quantities in the blood and have been extensively used in biomonitoring studies. German and Swiss researchers evaluated the sensitivity of DNA damage sensitivity in PBMCs to detect early-stage lung cancer in a cost-effective and patient-friendly manner. Participants pre...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on